These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Spuriously high phosphate level which is promptly resolved after plasmapheresis in a patient with multiple myeloma. Kiki I; Gundogdu M; Kaya H Transfus Apher Sci; 2007 Oct; 37(2):157-9. PubMed ID: 18037346 [TBL] [Abstract][Full Text] [Related]
6. Pseudohyperphosphatemia in a patient with multiple myeloma. Marcu CB; Hotchkiss M Conn Med; 2004 Feb; 68(2):71-2. PubMed ID: 15007869 [TBL] [Abstract][Full Text] [Related]
7. Monoclonal gammopathy and spurious hypophosphatemia. Weisbord SD; Chaudhuri A; Blauth K; DeRubertis FR Am J Med Sci; 2003 Feb; 325(2):98-100. PubMed ID: 12589234 [TBL] [Abstract][Full Text] [Related]
8. Measurement of serum-phosphate concentration in immunoglobulin G monoclonal gammopathy after PEG-precipitation. Chakraborty S; Kallner A Clin Chim Acta; 2015 Feb; 440():211-3. PubMed ID: 25490694 [TBL] [Abstract][Full Text] [Related]
9. Interferences in the measurement of circulating phosphate: a literature review. Molinaris V; Bianchetti MG; Milani GP; Lava SAG; Bruna RD; Simonetti GD; Faré PB Clin Chem Lab Med; 2020 Nov; 58(12):1971-1977. PubMed ID: 32549132 [TBL] [Abstract][Full Text] [Related]
10. Decreased anion gap associated with monoclonal and pseudomonoclonal gammopathy. Frohlich J; Adam W; Golbey MJ; Bernstein M Can Med Assoc J; 1976 Feb; 114(3):231-2. PubMed ID: 1032353 [TBL] [Abstract][Full Text] [Related]
11. Hyperglobulinemia with an increased anion gap. Kirschbaum B Am J Med Sci; 1998 Dec; 316(6):393-7. PubMed ID: 9856694 [TBL] [Abstract][Full Text] [Related]
12. Spurious hyperphosphatemia in patients with dysglobulinemia. Weinberg J; Adler AJ Miner Electrolyte Metab; 1989; 15(4):185-6. PubMed ID: 2761487 [TBL] [Abstract][Full Text] [Related]
13. The predictive power of serum kappa/lambda ratios for discrimination between monoclonal gammopathy of undetermined significance and multiple myeloma. Bergón E; Miravalles E; Bergón E; Miranda I; Bergón M Clin Chem Lab Med; 2005; 43(1):32-7. PubMed ID: 15653439 [TBL] [Abstract][Full Text] [Related]
14. Hyperphosphatemia in multiple myeloma due to a phosphate-binding immunoglobulin. Mandry JM; Posner MR; Tucci JR; Eil C Cancer; 1991 Sep; 68(5):1092-4. PubMed ID: 1913479 [TBL] [Abstract][Full Text] [Related]
16. Elimination of paraprotein interference in determination of plasma inorganic phosphate by ammonium molybdate method. Zaman Z; Sneyers L; Van Orshoven A; Blanckaert N; Mariën G Clin Chem; 1995 Apr; 41(4):609-14. PubMed ID: 7720254 [TBL] [Abstract][Full Text] [Related]
17. Pseudohyperphosphatemia in a hyperphosphatemic hemodialysis patient. Suchin EJ; Cizman B; Connolly BR; DiBattista WJ; Agus ZS Am J Kidney Dis; 2002 Nov; 40(5):E18. PubMed ID: 12407666 [TBL] [Abstract][Full Text] [Related]
18. Paraprotein interference with colorimetry of phosphate in serum of some patients with multiple myeloma. Sonnenblick M; Eylath U; Brisk R; Eldad C; Hershko C Clin Chem; 1986 Aug; 32(8):1537-9. PubMed ID: 3731447 [TBL] [Abstract][Full Text] [Related]
19. Significance of hyperglobulinemia in severe chronic liver diseases--with special reference to the correlation between serum globulin/IgG level and ICG clearance. Tanaka S; Okamoto Y; Yamazaki M; Mitani N; Nakqjima Y; Fukui H Hepatogastroenterology; 2007 Dec; 54(80):2301-5. PubMed ID: 18265652 [TBL] [Abstract][Full Text] [Related]
20. Prognostic factors and the effect of alkylating agents on survival in multiple myeloma. A review of 80 patients. Matzner Y; Benbassat J; Polliack A Isr J Med Sci; 1977 Aug; 13(8):797-807. PubMed ID: 408296 [No Abstract] [Full Text] [Related] [Next] [New Search]